Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
NEW YORK, May 26, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Intra-Cellular Therapies, Inc. securities (NASDAQ:ITCI) from August 12, 2014 through April 28, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Intra-Cellular Therapies investors under the federal securities laws.
To join the Intra-Cellular Therapies class action, go to http://www.rosenlegal.com/cases-1111.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; and (3) as a result, Intra-Cellular Therapies’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1111.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
